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To identify the specific domains of the presynaptic protein synapsin targeted by recently
described autoantibodies to synapsin.
Methods
Sera of 20 and CSF of two patients with different psychiatric and neurological disorders pre-
viously tested positive for immunoglobulin (Ig)G antibodies to full-length synapsin were
screened for IgG against synapsin I domains using HEK293 cells transfected with con-
structs encoding different domains of rat synapsin Ia. Additionally, IgG subclasses were
determined using full-length synapsin Ia. Serum and CSF from one patient were also
screened for IgA autoantibodies to synapsin I domains. Sera from nine and CSF from two
healthy subjects were analyzed as controls.
Results
IgG in serum from 12 of 20 IgG synapsin full-length positive patients, but from none of the
healthy controls, bound to synapsin domains. Of these 12 sera, six bound to the A domain,
five to the D domain, and one to the B- (and possibly A-), D-, and E-domains of synapsin I.
IgG antibodies to the D-domain were also detected in one of the CSF samples. Determina-
tion of IgG subclasses detected IgG1 in two sera and one CSF, IgG2 in none of the samples,
IgG3 in two sera, and IgG4 in eight sera. One patient known to be positive for IgA antibodies
to full-length synapsin had IgA antibodies to the D-domain in serum and CSF.
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Conclusions
Anti-synapsin autoantibodies preferentially bind to either the A- or the D-domain of synapsin I.
Introduction
By using a combination of immunoprecipitation methods, mass spectrometry, immunohis-
tochemistry of brain sections from wild type and synapsin-knock mice, as well as cell-based
assays and biochemistry we recently identified the presynaptic vesicle-associated protein
synapsin as a novel target of antineuronal autoantibodies in serum and CSF samples from a
patient with limbic encephalitis [1]. In a follow-up study using rat and human synapsin I trans-
fected HEK293 cells as well as biochemical analyses, serum IgG to full-length rat synapsin Ia
could be detected in 23 of 375 (6.1%) patients with different neurological and psychiatric dis-
eases, including patients with psychotic, bipolar or depressive disorders and multiple sclerosis
(MS) or clinically isolated syndrome (CIS), but not in 97 healthy controls [2]. Concomitant
serum autoantibodies, mostly low titer anti NMDAR antibodies, were detected in eight of the
patients.
Synapsin I and II are major synaptic vesicle proteins of the adult brain, regulating the avail-
ability of synaptic vesicles and thus affecting synaptic transmission [3; 4; 5]. Synapsins are
composed of different highly preserved domains that were defined by sequence homology
across species [6]. Synapsin Ia and Ib are two splice variants, which share the A-, B-, C- and D-
domains, but differ in the C-terminal region, consisting of the E domain in synapsin Ia and
the shorter F-domain in synapsin Ib (see also Fig 1A). Distinct functional roles, such as inter-
ference with the generation of excitatory postsynaptic potentials attributed to domain A of
synapsin I, were ascribed to individual domains of synapsin I [7]. Membrane insertion
involves domain C of synapsin I [8] and interaction with SH3 domain-containing endocytic
proteins was shown for the D-domain of synapsin I [9].
The pathophysiological relevance of antibodies to synapsin remains to be clarified. Our
finding that antibodies to synapsin are associated with different clinical phenotypes raises the
question whether this may be related to distinct functions of synapsin and to the recognition
of different domains of synapsin by autoantibodies to synapsin. To better understand the
potential pathophysiological relevance of antibodies to synapsin, we here characterized in
molecular detail the specific domains of synapsin targeted by synapsin autoantibodies.
Materials and methods
Ethical approval
The study was approved by the institutional review board of Charite´– Universita¨tsmedizin
Berlin (EA1/182/10; EA1/129/14, EA1/096/12) and the regional committee for medical and
health research ethics, central Norway (2011/137). All participants provided written informed
consent.
Patients
Patient sera investigated in this study were previously shown to contain antibodies to full-
length rat synapsin Ia and included sera from 16 patients positive for IgG autoantibodies to rat
synapsin Ia identified from a total of 207 patients admitted to acute psychiatric inpatient care
at the Department of Psychiatry, St. Olav’s University Hospital, Trondheim, Norway, between
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September 2011 and March 2012 [10]. Additionally, three sera and 1 CSF from three anti-
synapsin IgG positive patients with a clinically isolated syndrome (CIS) were available from a
cohort total of 78 patients with a CIS or early relapsing-remitting MS (RRMS) collected at the
NeuroCure Clinical Research Center/Department of Neurology, Charite´ –Universita¨tsmedizin
Berlin. The patients’ demographic and clinical findings were recently described in detail [2]. In
addition, we analyzed serum and cerebrospinal fluid (CSF) from the 69-year old male index
patient diagnosed with limbic encephalitis in 2013 in whom IgA and IgG autoantibodies to
synapsin I and II were originally identified [1]. As controls, nine sera and two CSF samples
from healthy subjects were obtained at the NeuroCure Clinical Research Center/Department
of Neurology, Charite´ –Universita¨tsmedizin Berlin.
Fig 1. Specific recognition of synapsin I domains expressed in transfected HEK cells by domain-specific antibodies. (A) Domain structure of the synapsin
isoforms Ia and Ib. The N-terminal domains A-C are highly conserved in all synapsins. The C-terminal region is variable due to heterogeneous combinations of
domains. (B) Diagram of the synapsin Ia fragments examined to investigate targeting of patient synapsin autoantibodies. (C-H) HEK293 cells were transfected
with rat synapsin Ia constructs, comprising the eYFP-tagged fragment ABC (C), eGFP-tagged BC (D), eGFP-tagged C (E), eGFP-tagged DE (F), eGFP-tagged D
(G), or eGFP-tagged E domain (H). Cells were fixed, permeabilized and incubated with antibodies either directed against the A-domain of synapsin I and II (rabbit
anti-synapsin A; dilution 1:500), the D-domain of synapsin I (mouse anti-synapsin D; dilution 1:500), the C-domain of synapsin I/II (rabbit anti-synapsin C;
dilution 1:500), or the E-domain of synapsin Ia (rabbit anti-synapsin E; dilution 1:200). Antibody binding was visualized using Alexa Fluor 549-coupled secondary
antibodies. Transfected cells were correctly recognized by the respective antibodies that colocalized with the signal of the tags, confirming domain identities and
detectability of the various domains by anti-synapsin antibodies.
https://doi.org/10.1371/journal.pone.0208636.g001
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Synapsin plasmids
The expression constructs for the various synapsin domains have been described earlier [6]. In
brief, domain cDNAs were cloned into either pEGFP or pEYFP C1-C3 vectors. The following
domains or domain combinations constituting sequence fragments of rat synapsin Ia (Uni-
Prot/SWISS-PROT AAA42145.1) were used in our study: pEYFP-ABC; pEGFP-BC; pEGFP-C;
pEGFP-D; pEGFP-DE and pEGFP-E. From the sequence of rat synapsin Ia, the following frag-
ments were constructed: these constructs contained the N-terminal ABC fragment (aa 1–416),
the BC fragment (aa 31–416), the C-domain (aa 113–420), the DE fragment (aa 415–704), the
D-domain (aa 414–651) and the E-domain (aa 655–704) (for detail see also Fig 1A, B). Rat full-
length synapsin Ia cDNA was tagged on the N-terminus with enhanced green fluorescent pro-
tein (eGFP) based on a pEGFP-C1 backbone.
Primary antibodies
A monoclonal mouse antibody against the D-domain of synapsin I (#106011) and a polyclonal
rabbit antibody against the A-domain of synapsin I/II (#106002) were purchased from Synap-
tic Systems (Go¨ttingen, Germany). Rabbit polyclonal antibodies against the C-domain of
synapsin I/II and the E-domain of synapsin Ia were developed by one of us (F.B.), as described
earlier [11]. A guinea pig polyclonal antibody against GFP used in some experiments to
enhance endogenous fluorescence was also obtained from Synaptic Systems (#132005).
Secondary antibodies
Mouse antibodies were visualized using Alexa Fluor 594 goat anti-mouse IgG (MoBiTec, Go¨t-
tingen, Germany; # A11032). An Alexa Fluor 488 goat anti-guinea pig IgG (#A11073) was also
from MoBiTec. Alexa Fluor 594 goat anti-rabbit IgG (#A11037; Life Technologies, Carlsbad,
CA, USA) was applied to detect bound rabbit antibodies. Bound human antibodies of the
immunoglobulin type G (total) were visualized by incubation with Alexa Fluor 594 labeled
goat anti-human IgG directed against the Fc fragment (Dianova GmbH, Hamburg, Germany;
#109-585-008). Visualization of human IgG subclass-specific antibodies was achieved using
Alexa Fluor 647 labeled goat anti-human IgG1, IgG2, IgG3 and IgG4 antibodies (Southern Bio-
tech, Birmingham, USA; #9052–31, #9070–31, #9210–31, #9200–31). Detection of immuno-
globulin A antibodies in the patients’ CSF or serum was performed by using a Texas Red 594
coupled goat anti-human IgA secondary antibody (Dianova; #109-076-011).
Cell-based assays for synapsin domains and full-length synapsin Ia
Human embryonic kidney (HEK) 293 cells were cultured in 24-well multiplates to 70% con-
fluency and transfected with 0.5–1 μg plasmid cDNA per well for 24 hours using Lipofecta-
mine (Gibco/BRL Life Technologies, Eggenstein, Germany). Transfected cells were fixed with
ice-cold 80% methanol for 20 minutes at -20˚C (or 4% paraformaldehyde at 4˚C for detection
of IgA immunoreactivity). Cells were subsequently permeabilized with 0.1% Triton X-100.
Thereafter, cells were incubated with either the domain specific primary antibodies at the indi-
cated concentrations or with patient or control serum or CSF at a dilution of 1:320.
Antibody index calculation
HEK 293 cells transfected with rat synapsin Ia were processed as described above and incu-
bated with increasing dilutions (1:320, 1:1000, 1:3200, 1:10.000, and 1:32,000) of patient CSF
or serum to determine titers of anti-synapsin IgG in a paired CSF/serum sample. Alexa Fluor
594 goat anti-human IgG served as secondary antibody. Antibody index (AI) for IgG
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antibodies to synapsin Ia was calculated as previously described by the formula: AI = (anti-
synapsin titer CSF-1/anti-synapsin titer serum-1)/(total Ig CSF/total Ig serum). AI values above
four were considered as evidence of an intrathecal antibody synthesis [12].
Results
Cell-based assays for detection of antibodies to synapsin I domains
From the sequence of rat synapsin Ia, six different combinatory domain fragments or single
domains were constructed (Fig 1A and 1B). A rationale to use fragments from rat synapsin
sequence was the fact that these constructs have been extensively characterized for targeting
and binding to presynaptic terminals [6]. Of note, human and rat synapsin I share a 95% iden-
tity of the primary structure [13] and binding of patient antibodies to rat and human protein
exhibited a very similar pattern [2].
To establish cell-based assays for the detection of antibodies to synapsin I domains, we
transfected six different rat synapsin Ia constructs (Fig 1B) in human embryonic kidney
(HEK) 293 cells. Subsequently, transfected cells were incubated with antibodies specifically
recognizing the A-, C-, D- or E-domain of synapsin I.
As shown in Fig 1C–1H all six synapsin I fragments were clearly detectable by their endoge-
nous fluorescence tags (eYFP for the ABC-fragment and eGFP for all other constructs). Fur-
thermore, all individual or combined synapsin Ia domains were specifically recognized by
antibodies directed against the respective domains indicating proper assay function.
Antibodies to synapsin predominantly target the A- or D-domain of
synapsin Ia
To decipher the domain specificity of autoantibodies to synapsin Ia, we analyzed a total of 20
serum and two CSF samples, which contained antibodies to full-length rat synapsin Ia as iden-
tified in our previous studies [1; 2]. For control, nine sera and two CSF samples from healthy
controls were analyzed as well.
We first screened sera and one CSF from 19 patients positive for rat synapsin IgG for their
reactivity with the various synapsin domains. Sixteen of these patients were diagnosed with
psychiatric disorders and three patients with a CIS. CSF was available from one of the patients
with a CIS. A summary of the findings is presented in Table 1.
Out of the sera of 16 patients with psychiatric disorders positive for antibodies to full-length
synapsin, 11 sera exhibited a detectable immunoreactivity against one or more of the synapsin
Ia domains. Out of the three patients diagnosed with a CIS, serum and CSF from one patient
showed immunoreactivity to synapsin Ia domains. Among these 12 positive sera, seven were
positive for the ABC fragment (58,3%). Among these seven sera, only one serum was also posi-
tive for the BC fragment and none was positive for the single C-domain. Thus, sera of six
patients were likely exclusively positive for the A-domain (as exemplarily shown for one
patient in Fig 2A) and one proved to be positive for both the A- and B-domains, or solely the
B-domain (PSY_0149, the only patient with multiple targeted domains, Table 1). A direct
approach towards testing reactivity to the A- or B-domain alone was not possible due to the
lack of individual constructs for these domains. The only serum that reacted with both the
ABC and the BC fragment also reacted with the C-terminal domains D and E.
The five sera (41,7%) that did not react with the ABC fragment exhibited reactivity to either
the DE fragment and the D-domain (three), the DE fragment alone (one) or the D-domain
alone (one). None of these five sera showed reactivity towards the E-domain alone, indicating
that the D-domain was the targeted antigenic region of synapsin Ia. A CSF sample available
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from a patient whose serum reacted with the DE fragment and the D-domain likewise reacted
with the DE fragment and the D-domain. The results of the cell-based assays for this patient
with a CIS are shown in Fig 2B. For this patient, antibody titers of the serum/CSF pair were
determined using full-length synapsin Ia and the antibody index (AI) was calculated. The AI
value of 19,6 clearly indicated an intrathecal synthesis of IgG to synapsin I. Additionally, all
nine control sera and two CSF samples applied at the same dilution as the patients’ sera were
negative for IgG synapsin autoantibodies, as exemplarily shown for two healthy subjects in Fig
2C.




























CIS_0036 f 34 - - - - - - 1:3200
Clinically isolated syndrome; panic/anxiety and recurrent depressive disorder
CIS_0064 f 51 - - - - - - 1:1000 Clinically isolated syndrome
CIS_0117
serum,
f 24 - - - + + - 1:10000 Clinically isolated syndrome
CIS_0117
CSF
„ „ - - - + + - 1:1000 „
PSY_0012 f 29 + - - - - - 1:320 Bipolar affective disorder type 1, mixed episode
PSY_0032 f 20 + - - - - - 1:320 Bipolar affective disorder type 2, depressive episode
PSY_0045 f 32 - - - - - - 1:1000
Persistent personality change after catastrophic experience
PSY_0068 f 52 - - - + - - 1:10000
Recurrent depressive disorder, severe episode; coma for 12 days at age 8 years
after accident
PSY_0082 m 26 - - - - - - 1:320 Acute polymorphic psychotic disorder; Mo¨bius syndrome
PSY_0094 m 39 - - - - + - 1:100000
Alcohol abuse, ADHD, bipolar affective disorder type 2, emotionally unstable
personality disorder
PSY_0141 f 21 - - - + + -
1:1000 Alcohol dependency syndrome, ADHD, PTSD, mixed obsessional thoughts and
acts
PSY_0149 m 51 + + - + + +
1:100000 Bipolar affective disorder type 1, manic episode; alcohol dependency syndrome;
hepatitis C
PSY_0171 f 22 - - - + + - 1:32000 Moderate depressive episode; SLE
PSY_0183 f 31 - - - - - - 1:3200 Recurrent depressive disorder, moderate episode; personality disorder
PSY_1851 f 58 + - - - - - 1:1000 Bipolar disorder type 1, manic episode with psychotic symptoms; MS; later
diagnosed organic affective disorder
PSY_1852 m 68 + - - - - - 1:320 Bipolar affective disorder type 1, manic episode; paranoid psychosis
PSY_0189 f 77 + - - - - - 1:3200 Recurrent depressive disorder
PSY_0201 f 44 - - - - - - 1:1000
Recurrent depressive disorder, moderate episode; alcohol dependency syndrome;
epileptic seizures as child; probably anoxic injury during birth
PSY_0203 m 27 + - - - - - 1:320 Paranoid schizophrenia; multiple drug abuse
PSY_0204 m 60 - - - - - - 1:1000
Recurrent depressive disorder, mild episode; cannabinoid abuse; melanoma;
hepatitis C; psoriasis
Presence (+) or absence (-) of immunoreactivity is indicated.
Diagnoses, antibody titers to full length synapsin and concomitant autoantibodies (not shown) have been published previously [2].
ADHD = attention deficit hyperactivity disorder; f = female; m = male; MS = multiple sclerosis; PTSD = post traumatic stress disorder; SLE = systemic lupus
erytematodus
https://doi.org/10.1371/journal.pone.0208636.t001
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Fig 2. Serum IgG autoantibodies against the A-domain of a patient with bipolar affective disorder and serum and
CSF IgG autoantibodies against the D-domain of a patient with a clinically isolated syndrome (CIS). (A) HEK293
cells were transfected with eYFP-tagged synapsin I fragment ABC, eGFP-tagged DE, BC or C. Cells were incubated
with patient serum at a dilution of 1:320. Bound IgG was detected using an Alexa 594-coupled secondary antibody to
the Fc fragment of human IgG. The patient’s serum demonstrated positive immunoreactivity that co-localized with the
eYFP tag of synapsin ABC, but with none of the other constructs. (B) HEK293 cells were transfected with eYFP-tagged
synapsin I fragment ABC, eGFP-tagged DE, D or E. Cells were incubated with patient serum or CSF at a dilution of
1:320. Bound IgG was detected using an Alexa 594-coupled secondary antibody to the Fc fragment of human IgG. Both
the patient’s serum and CSF demonstrated positive immunoreactivity that co-localized with the eGFP tag of synapsin
DE and the single D-domain, but with none of the other constructs. (C) Serum and CSF of two healthy controls
(control IgG) did not bind to cells transfected with synapsin ABC or DE.
https://doi.org/10.1371/journal.pone.0208636.g002
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Of note, all patient and control samples were also tested for IgA reactivity to the ABC and
DE fragments. All samples remained negative, thereby confirming our previous results
obtained for full-length synapsin [2]. As a further control, 10 patient sera from that study nega-
tive for antibodies to full-length synapsin were tested for IgG and IgA reactivity to the ABC or
DE fragment. Also in this case no reactivity to one of the fragments was detected.
IgA antibodies from the index patient with limbic encephalitis target the
D-domain of synapsin Ia
We also analyzed serum and CSF from our index patient, who had high titers of anti-synapsin
IgA and IgG in serum and CSF [1]. Both serum and CSF IgA clearly reacted with the DE frag-
ment and the D-domain, but not with the ABC or E construct (Fig 3A). Of note, we could not
detect reactivity of IgG antibodies to any of the domains despite the fact that serum and CSF
IgG reacted with full-length synapsin. Serum and CSF IgA from two healthy subjects did not
react with any of the synapsin constructs (Fig 3B).
After successful determination of domain specificities we additionally aimed to identify the
respective IgG subclasses involved in autoimmunity against synapsin. To this end, we trans-
fected HEK 293 cells with full-length synapsin Ia, again incubated fixed cells with patient sera
that reacted with any of the fragments as well as with the CSF of CIS117 at a dilution of 1:320
and applied secondary antibodies specific for the four subclasses IgG1, IgG2, IgG3 and IgG4
(Fig 4A–4C). As a result, 1 serum and the corresponding CSF exclusively contained IgG1, 2
sera exclusively showed IgG3 reactivity, 7 sera only showed IgG4 reactivity, and one serum was
positive for IgG1 and IgG4. No IgG2 reactivity was observed (for summary, see Table 2). Note-
worthy, the patient with two IgG subclasses was identical with the patient that exhibited
immunoreactivity to more than one domain. One single serum (patient PSY_203) yielded no
clearly interpretable results and was therefore excluded from the summary in Table 2. Overall,
no strict correlation of one of the subclasses with a single domain was observed.
Demographical data of patients with synapsin autoantibodies
The diagnoses, clinical and paraclinical findings of all synapsin-positive patients have been
published in our previous studies. In the current study 13 (eight females, five males) out of 20
patients exhibited immunoreactivity to fragments of synapsin Ia and had a mean ± SD (range)
age of 42,9 ± 19,8 (20–77) years. Controls (nine) had a mean ± SD (range) age of 38,6 ± 17,2
(18–65) years.
Discussion
Despite the apparent clinical heterogeneity, a preference in epitope specificity of anti synapsin
autoantibodies in psychiatric and neurological patients exists. Of the 13 patients showing a
clearly detectable immune reaction to one of the investigated synapsin fragments six sera
exhibited binding of IgG to the A-domain. The same number was detected for the D-domain.
Binding to the B-domain and E-domain was shown for one individual patient. Concerning
IgG subclasses, IgG1, IgG3 and, with highest prevalence, IgG4 were detected.
Intracellular synaptic proteins as autoimmune targets: Pathogenic
relevance
Given the fact that synapsin is a ubiquitous presynaptic protein, occurrence of autoantibodies
in a variety of psychiatric and neurological disorders is conceivable. Subject to functional evi-
dence, it remains unclear if the existence of autoantibodies to synapsin in serum or CSF has a
Autoantibodies and synapsin domains
PLOS ONE | https://doi.org/10.1371/journal.pone.0208636 December 13, 2018 8 / 14
pathogenic relevance or represents an epiphenomenon. In addition, it remains to be elucidated
whether the antigenic epitope presentation of synapsin domains relies on the extracellular pre-
sentation of synapsin in the course of an ongoing neuronal repair mechanism as proposed in
an in vivo model [14], a specific extracellular presentation by a so far unknown surface trans-
port process or just results from neuronal cell loss. Irrespective of how the immune system
gets access to synapsin, an intracellular action of antibodies might occur, as shown for autoan-
tibodies against neurofilament proteins [15]. In contrast to other known autoantibodies to
intracellular target proteins such as anti-Hu, anti-Ri or anti-Yo, [16; 17; 18] no strong tumor
Fig 3. IgA antibodies to synapsin in serum and CSF of the previously described index patient with limbic
encephalitis are directed against the D-domain of synapsin. (A)HEK293 cells were transfected with eYFP-tagged
synapsin I fragment ABC, eGFP-tagged DE, D or E. Cells were incubated with patient serum or CSF at a dilution of
1:320. Bound patient IgA was detected using a Texas red-coupled secondary antibody directed against human IgA.
Both the patient’s serum and CSF (Patient IgA) demonstrated positive immunoreactivity that co-localized with the
eGFP tag of synapsin DE and single D fragments, but with none of the other constructs. (B) Serum and CSF of two
healthy controls (control IgA) did not bind to the cells transfected in the same way.
https://doi.org/10.1371/journal.pone.0208636.g003
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association was detectable in patients with autoantibodies to synapsin. Moreover, the index
patient clinically improved following immunotherapy indicating a functional relevance of anti
synapsin antibodies [1]. Hitherto, autoantibodies to intracellular synaptic proteins other than
synapsin have already been described for glutamate decarboxylase 65 (GAD65) and amphi-
physin in large patient cohorts [19; 20]. For these two autoantibodies associated with different
neurological diseases like stiff-man syndrome evidence for a pathogenic potential was sug-
gested by rodent animal models showing induction of anxiety by transfer of stiff-person IgG
[21] or a reduced GABAergic inhibition by amphiphysin IgG [22]. Internalisation of amphi-
physin antibodies was shown recently to reduce the presynaptic vesicle pool, adding to mecha-
nistic understanding of a suggested pathogenic effect [23]. In the case of synapsin, a putative
pathogenic mechanism of antibody binding might rely on the interference with the phosphor-
ylation status of synapsin, a modification crucially involved in regulating its function and
shown to affect residues both of the A and the D domain regions [24].
When comparing the clinical diagnoses, antibodies to the D-domain were observed in a
somewhat broader spectrum of diseases (depression, bipolar disorder, ADHD, CIS, limbic
Fig 4. IgG subclasses of antibodies to synapsin in sera of patients with a clinically isolated syndrome (CIS), bipolar disorder
and depression. (A) HEK293 cells were transfected with eGFP-tagged full length rat synapsin Ia and incubated with serum of
patient CIS117 at a dilution of 1:320. Bound antibodies of the IgG subclasses IgG1-4 were detected using subclass-specific Alexa
647-coupled secondary antibodies. The patient’s serum demonstrated positive immunoreactivity for IgG1 antibodies but none of the
other subclasses. (B) HEK293 cells were transfected with eGFP-tagged full length rat synapsin Ia and incubated with serum of
patient PSY 149 (upper two panels) and patient PSY 171 at a dilution of 1:320. Bound antibodies of the IgG subclasses IgG1-4 were
detected as given in (A). Serum of patient PSY 149 demonstrated positive immunoreactivity for IgG1 and IgG4 antibodies but none
of the other subclasses. Serum of patient PSY 171 demonstrated positive immunoreactivity for IgG3 antibodies but none of the other
subclasses. (C) Serum of a healthy control did not exhibit immunoreactivity for any of the IgG subclasses.
https://doi.org/10.1371/journal.pone.0208636.g004
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encephalitis) than antibodies to the A-domain, that dominated in bipolar disorder patients
(four out of six patients). The relatively small number of patients, however, prevents us from
drawing definite conclusions on the association of specific diseases with antibodies to distinct
synapsin domains.
In addition to our previous prevalence study that addressed the presence of antibodies in
serum we had one additional CSF sample available for testing (CIS_0117). As shown for IgA
antibodies of the index patient with limbic encephalitis this CSF also showed IgG reactivity to
the D-domain. Future studies are needed to show whether the D-domain is the preferred tar-
get of CSF antibodies. Noteworthy, for both available CSF samples with antibodies to synapsin
an intrathecal synthesis of immunoglobulins could be detected in this study and [1].
Antibodies to full length synapsin not reacting with single domains or
domain stretches
The observation that seven out of 20 sera reacting with full-length synapsin Ia did not react
with distinct synapsin domains might be explained by the fact that a certain conformational
epitope structure can be provided only by the full-length protein. Missing homology between
human and rat sequences can be ruled out to account for this observation since all 20 sera
reacted with full length rat synapsin. Alternatively, anti synapsin antibodies may exhibit a
lower affinity to the expressed domains than to the full-length protein and therefore escaped
detection in our assay, that was standardized to yield a high signal to noise ratio based on a
1:320 dilution of the applied patient samples. Antibody titers to full length protein were ini-
tially analysed for all individual sera [2] but can not be used to predict the binding probability
to individual domains since sera with a titer range of 1:320–1:100.000 bound to synapsin frag-
ments. Folding differences between the individual synapsin constructs might also account for
the observation that two sera exclusively reacted with either the DE fragment or the D-domain
but not with both constructs as expected.
Distinct IgG subclasses
Of the four IgG subclasses described in the literature we were able to detect IgG1 (two
patients), IgG3 (two patients) and, most frequently, IgG4 (eight patients) in our cohort. Despite
Table 2. Distinct IgG subclasses of antibodies to synapsin Ia.
Patient IgG1 IgG2 IgG3 IgG4 Target Domain
CIS117 (serum) + - - - D
CIS117 (CSF) + - - - D
PSY_0012 - - - + A
PSY_0032 - - - + A
PSY_0068 - - - + D
PSY_0094 - - - + D
PSY_0141 - - - + D
PSY_0149 + - - + A,B,D,E�
PSY_0171 - - + - D
PSY_1851 - - - + A
PSY_1852 - - - + A
PSY_0189 - - + - A
Presence (+) or absence (-) of immunoreactivity is indicated.
� Differential attribution of IgG1 and IgG4 antibodies to individual domains is unknown.
https://doi.org/10.1371/journal.pone.0208636.t002
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being the last prevalent subclass detected in serum [25] IgG4 antibodies therefore seem to be
the dominant, albeit not exclusive, subclass in synapsin autoimmunity, at least for the relatively
few cases described so far. So, the ability to fix complements seems not to be necessary for the
immune reaction in the majority of patients. Antibodies of the IgG4 subclass have already been
described for LGI1 and Caspr2 encephalitis [26; 27], and DPPX encephalitis [28]. Moreover,
this subclass is associated with an IgG4-related systemic disease, able to cause pancreatitis and
infection of other organs [29, 30].
In summary, the present study adds data to further characterize the recently identified anti-
neuronal antibodies against synapsin in molecular detail. Functional cell culture and animal
studies investigating the pathological potential of these antibodies by electrophysiological and
biochemical methods are under way to shed light on the putative pathogenic impact of these
antibodies.
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